Brian Chapin, MD

Experts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.

Drs Helfand, Chapin, and Collins, review the case of 67-year-old man treated with recurring prostate cancer.

Clinical oncologists present the case of a 62-year-old man with recurrent prostate cancer.

Experts in prostate cancer evaluate the data from the SPOTLIGHT trial and the use of 18F-rhPSMA-7.3 for prostate cancer.

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.

Oncologists share their clinical perspectives of PSMA PET imaging and the results of the patient case.

A panel of experts in prostate cancer present the case of a 51-year-old man with high-risk localized prostate cancer.

Dr Helfand and panelists outline the incorporation of multidisciplinary approaches to the management of prostate cancer.

Clinical oncologists share their best practices for the utilization of PSMA-targeted agents in patients with prostate cancer.

A comprehensive discussion surrounding the clinical development of PSMA-targeted therapies for patients with prostate cancer.

Expert oncologists give an overview of prostate-specific membrane antigen (PSMA) and discuss its utility for the treatment of prostate cancer.

A panel of expert oncologists in prostate cancer give an overview of the evolution of imaging techniques used for patients with prostate cancer.